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Time-Dependence of Risperidone and Asenapine Sensitization
and Associated D2 receptor Mechanism
Jun Gao and Ming Li*
Department of Psychology, University of Nebraska-Lincoln, USA
Abstract
When an antipsychotic drug is given repeatedly and intermittently, there is often a long-term
increase in its behavioral efficacy, termed antipsychotic sensitization. With the passage of time,
the magnitude of antipsychotic sensitization may increase or decrease depending on the principle
of Time-Dependent Sensitization (TDS) or memory decay, respectively. In the present study, we
examined the time-dependent feature and possible dopamine D2 receptor mechanism of
sensitization induced by the antipsychotics risperidone and asenapine in the conditioned avoidance
response test. Well-trained male adult Sprague-Dawley rats were first repeatedly treated with
risperidone (1.0 mg/kg) or asenapine (0.2 mg/kg) and tested for avoidance response daily for 5
consecutive days. Eight, 18 or 38 days after the 5th drug treatment, all rats were retested drug-free
to assess the residual impact of prior risperidone or asenapine treatment. Drug-pretreated rats had
significantly lower avoidance than vehicle-pretreated ones on this test, and the group differences
increased with the passage of time. In the subsequent drug challenge test at 10, 20 or 40 days after
the 5th drug treatment, all rats were injected with a low dose of risperidone (0.3 mg/kg) or
asenapine (0.1 mg/kg). Drug-pretreated rats again made significantly less avoidances than
controls, confirming the drug-induced sensitization effect. Finally, in the quinpirole (a D2/3
receptor agonist, 1.0 mg/kg, sc)-induced hyperlocomotion test, risperidone-pretreated rats
exhibited a significantly higher level of motor activity than the vehicle-pretreated ones. These
findings suggest that risperidone and asenapine sensitization is long-lasting, follows the TDS
principle, and is likely mediated by D2 receptor supersensitivity.
Keywords
Time-Dependent Sensitization (TDS); Asenapine; Risperidone; Conditioned avoidance response;
Quinpirole; Locomotor activity
1. Introduction
It is well documented that repeated and intermittent administrations of most antipsychotic
drugs often cause an increase in the behavioral responsiveness to these drugs. This
phenomenon is termed antipsychotic sensitization. Supersensitivity psychosis, tardive
dyskinesia, and time-dependent increase in antipsychotic response are several well-known
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clinical examples of antipsychotic sensitization [1-3]. In preclinical studies, antipsychotic
sensitization has been demonstrated in several different behavioral models [4-7]. It is often
measured using two different methods[8] similar to those for assessing psychostimulant-
induced behavioral sensitization[9]. The first index of antipsychotic sensitization is revealed
through a within-subjects comparison, in which the behavioral effect of a drug treatment is
stronger on the last treatment day than the first day (i.e., a comparison between days 1 and
5). The second index of antipsychotic sensitization is provided by a between-subjects
comparison, in which the behavioral response of drug-pretreated animals to a challenge dose
of an antipsychotic drug is compared to the response of vehicle-pretreated control animals.
Here, antipsychotic sensitization is demonstrated by an increased sensitivity to the drug
challenge in drug-pretreated animals relative to those pretreated with vehicle.
The conditioned avoidance response (CAR) model is an aversion motivated instrumental
conditioning model, which is traditionally used in in the preclinical study of antipsychotic
drugs (APDs) [10, 11]. In this model, animals can be trained to prevent the occurrence of an
aversive stimulation (e.g. electric footshock) by performing a specific response to a
conditioned stimulus (e.g. tone). This response is thought to reflect a persecutory delusion
[12]. The treatment of antipsychotic drugs selectively disrupts avoidance responding without
altering unconditioned escape response [13, 14], and thus this test has high predictive
validity for antipsychotic efficacy [15]. This feature has been effectively used to identify
potential antipsychotic drugs, to differentiate antipsychotic drugs from other classes of
psychotropic drugs, and to predict the clinical potency of antipsychotic drugs [11, 14,
16-18]. Our work focuses on behavioral characteristics and neurobiological mechanisms of
antipsychotic sensitization in the conditioned avoidance response (CAR) and phencyclidine
(PCP)-induced hyperlocomotion models, two animal behavioral tests sensitive to
antipsychotic activity [8, 19-23]. We have shown that repeated administration of
haloperidol, olanzapine, asenapine or risperidone daily for 5-7 days tends to cause a
progressively increased inhibition of avoidance responding and PCP-induced
hyperlocomotion over days (a within-subjects sign of sensitization). A few days later, when
all rats are given a challenge dose of these drugs, they often make significantly fewer
avoidance responses and exhibit lower PCP-induced hyperlocomotion than those that are
treated with these drugs for the first time (a between-subjects sign of sensitization). In
addition, our previous studies also indicate that repeated administration of haloperidol and
olanzapine causes a sensitization effect that can last up to 17 days [8], and are likely
mediated by dopamine D2 and 5-HT2A receptor-related neural plasticity [24]. Recently, we
further show that olanzapine sensitization can be induced in adolescent rats and this effect
can last up to 45 days and persist into adulthood [21].
Antipsychotic sensitization likely reflects a composite impact from two sources. One is the
relatively specific pharmacological actions of a given antipsychotic drug. As mentioned
before, this is likely mediated by a drug’s actions on its immediate neuroreceptor targets
(e.g. D2 and 5-HT2A receptors) [24] and should follow the basic principles of learning and
memory, as antipsychotic sensitization represents a non-associative form of learning and
memory. Under this principle, the magnitude of sensitization should decrease with the
passage of time due to a memory trace decay process (similar to forgetting). Another source
is the ubiquitous adaptive response to the foreign aspect of the drug (any drug is an
exogenous agent to an organism), which tends to follow the “Time-dependent Sensitization
(TDS)” principle. This principle, first articulated by Antelman and his colleagues [25],
suggests that a drug effect often grows (i.e. sensitized or strengthened) with the passage of
time upon acute exposure to the drug. In Antelman’s earlier work, he found that a single
exposure to a clinically low dose of antipsychotic produced changes that were shown up to 8
weeks later [6]. In our previous study on the time course of antipsychotic sensitization [8],
we assessed the magnitude of haloperidol and olanzapine sensitization in the conditioned
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avoidance response test at 4, 10, or 17 days after the last drug treatment. We did not find that
haloperidol or olanzapine sensitization changed its magnitude over time, but maintained at a
high level throughout the post-injection period. One limitation of the study was shorter time
courses tested. It is possible that with a prolonged period of testing, the time-dependent
feature of antipsychotic sensitization could be revealed.
The present study addressed this limitation by examining the potential time-dependent
feature of antipsychotic sensitization induced by risperidone and asenapine, which represent
the earliest and latest atypical antipsychotic drugs in a broader time frame. Both drugs are
medically approved for the treatment of schizophrenia and bipolar disorders, with a multiple
receptor binding profile targeting dopamine D2 and D1 receptors, serotonin receptors (5-
HT2A, 5-HT2C, 5-HT7), adrenergic α1 and α2 receptors, histamine H1 and H2 receptors, etc.
[26, 27]. Both drugs have shown to give rise to a sensitization effect in animal tests of
antipsychotic activity, including conditioned avoidance test and PCP-induced
hyperlocomotion. We also investigated the involvement of dopamine D2 receptor as a
biological mechanism underlying antipsychotic sensitization by comparing the quinpirole-
induced increase in motor activity in drug-pretreated animals to vehicle-pretreated animals.
Because quinpirole is a selective D2/3 receptor agonist, a higher level of motor activity under
quinpirole challenge presumably reflects an upregulation of D2 receptor function [28, 29].
Quinpirole-induced hyperlocomotion is also thought to be mediated through an increase in
the efficacy of the post-synaptic D2/3 transductional mechanisms [30, 31], and has been
widely used to assess drug or non-drug induced changes in D2/3 functions [32, 33].
2. Materials and methods
2.1. Animals
Adult male Sprague-Dawley rats (226-250g upon arrival, Charles River, Portage, MI) were
housed two per cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages under
12-h light/dark conditions (light on between 6:30am and 6:30pm). Room temperature was
maintained at 22 ± 1°C with a relative humidity of 45-60%. Food and water was available
ad libitum. Animals were allowed at least 5 days of habituation to the animal facility before
being used in experiments. All behavioral tests took place between 9 am and 5 pm in the
light cycle. All experimental treatment and procedures were approved by the Institutional
Animal Care and Use Committee at the University of Nebraska-Lincoln.
2.2. Drugs and choice of doses
Risperidone (RIS) (a gift from the NIMH drug supply program) was dissolved in distilled
sterile water with 1.0% glacial acetic acid. Asenapine Maleate (ASE) (a gift from the NIMH
drug supply program) and quinpirole hydrochloride (Tocris Bioscience, Bristol, UK) were
dissolved in 0.9% saline. All drugs were administered subcutaneously in a volume of 1.0 ml/
kg body weight. Doses of RIS (1.0 and 0.3 mg/kg, for drug test and challenge respectively)
and ASE (0.2 and 0.1 mg/kg, for drug test and challenge respectively) were chosen on the
basis of literature review showing that these doses produce a reliable disruption of avoidance
responding and cause a sensitization effect [23, 34-39]. The chosen quinpirole dose (1.0 mg/
kg) targets post-synaptic D2 receptors and causes an increase in motor activity [29, 40-42].
2.3. Two-way avoidance conditioning apparatus
Ten identical two-way shuttle boxes custom designed and manufactured by Med Associates
(St. Albans, VT) were used. Each box was housed in a ventilated, sound-insulated isolation
cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm long, 30 cm high
(from grid floor), and 24 cm wide, and was divided into two equal-sized compartments by a
partition with an arch style doorway (15 cm high × 9 cm wide at base). A barrier (4 cm high)
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was placed between the two compartments, so the rats had to jump from one compartment to
the other. The grid floor consisted of 40 stainless-steel rods with a diameter of 0.48 cm,
spaced 1.6 cm apart center to center, through which a scrambled footshock (as an
unconditioned stimulus, US; 0.8mA, maximum duration: 5 s) was delivered by a constant
current shock generator (Model ENV-410B) and scrambler (Model ENV-412). The rat
location and crossings between compartments were monitored by a set of 16 photobeams
(ENV-256-8P) affixed at the bottom of the box (3.5 cm above the grid floor). Illumination
was provided by two houselights mounted at the top of each compartment. The conditioned
stimulus (CS, i.e. 76 dB white noise) was produced by a speaker (ENV 224 AMX) mounted
on the ceiling of the cubicle, centered above the shuttle box. Background noise
(approximately 74 dB) was provided by a ventilation fan affixed at the top corner of each
isolation cubicle. All training and testing procedures were controlled by Med Associates
programs running on a computer.
2.4. Locomotor activity monitoring apparatus
Sixteen activity boxes were housed in a quiet room. The boxes were 48.3 cm × 26.7 cm ×
20.3 cm transparent polycarbonate cages, which were similar to the home cages but were
each equipped with a row of 6 photocell beams (7.8 cm between two adjacent photobeams)
placed 3.2 cm above the floor of the cage. A computer with recording software (Aero
Apparatus Sixbeam Locomotor System v1.4, Toronto, Canada) was used to detect the
disruption of the photocell beams and recorded the number of beam breaks. All experiments
were run during the light cycle.
2.5. Experiment 1: Effect of time interval between initial drug exposure and subsequent
drug challenge on the strength of risperidone sensitization
This experiment examined the time course of the risperidone sensitization effect in the CAR
model. The experiment was comprised of the following three phases: Avoidance training,
five days of repeated risperidone testing and risperidone challenge test. Figure 1 depicts the
experimental procedure and groups at different phases of this experiment.
Avoidance training—Sixty-four rats were first habituated to the CAR boxes for 2 days
(20 min/day). They were then trained for conditioned avoidance responding for 10 sessions
(1 session/day). Each session consisted of 30 trials. Every trial started by presenting a white
noise (CS) for 10 s, followed by a continuous scrambled foot shock (0.8 mA, US, maximum
duration = 5 s) on the grid floor. An avoidance response was recorded if a subject moved
from one compartment into the other within the 10 s of CS presentation (before the shock).
An escape response was recorded if the rat remained in the same compartment for more than
10 s and made a crossing upon receiving the footshock. If the rat did not respond during the
entire 5 s presentation of the shock, the trial was terminated and the intertrial intervals
started. The total number of avoidance responses was recorded for each session. Inter-trial
intervals varied randomly between 30 and 60s.
Five days of repeated risperidone testing—At the end of the training session, 51 rats
acquired a robust avoidance responding (≥ 70% avoidance in each of the last 2 sessions).
They were matched on the level of avoidance and then randomly assigned into 6 groups (n =
8-9/group): 2 ten-day groups (VEH D10 and RIS D10), 2 twenty-day groups (VEH D20 and
RIS D20) and 2 forty-day groups (VEH D40 and RIS D40). They were then tested daily
under the CS-only (no shock, 30 trials/session) condition for 5 consecutive days, following
the same procedure as employed before [8, 19, 22, 43]. On each test day, rats were first
injected with vehicle (VEH; sterile water with 1.0% glacial acetic acid) or RIS (1.0 mg/kg)
sc and tested in the CAR boxes 1 h later.
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Risperidone challenge test—After the last (5th) drug test session, rats were undisturbed
in their home cages for either 7 (for the VEH D10 and RIS D10 groups), 17 (for the VEH
D20 and RIS D20 groups) or 37 (for the VEH D40 and RIS D40 groups) days. They were
then given 2 drug-free avoidance retraining sessions (one CS-only session and one CS-US
session) to bring their avoidance responses back to the pre-drug level before the challenge
test. These retraining sessions also served as a test for the residual impact of prior RIS
treatment on avoidance responding. One day later, rats in each group pair (e.g. VEH D10
and RIS D10) were injected with RIS at 0.3 mg/kg and tested for avoidance performance in
the CS-only condition (30 trials) 1 h later.
2.6. Experiment 2: Effect of prior risperidone treatment on quinpirole-induced
hyperlocomotion
Forty-eight rats randomly selected from 51 used in Experiment 1 were used in this
experiment. They included 8 rats from each of the 6 groups: RIS D10, VEH D10, RIS D20,
VEH D20, RIS D40, and VEH D40 (n = 8/group). As shown in Figure 1, 48 days after the
last (5th) RIS test, all rats were first habituated to the locomotor activity apparatus for 2 days
(30 min/day), on the second day, all rats were injected with saline before putting into the test
chambers. One day later, they were injected with quinpirole (1.0 mg/kg, sc) and immediately
placed in the test apparatus for 120 min. Locomotor activity (number of photobeam breaks)
was measured in 10-min blocks throughout the entire 120-min test period.
2.7. Experiment 3: Effect of time interval between initial drug exposure and subsequent
drug challenge on the strength of asenapine sensitization
This experiment examined the time course of asenapine sensitization using an identical
procedure as that in Experiment 1. Fifty-three rats that had met the training criterion (out of
an initial 60 rats that were trained) were matched and assigned into 6 groups (n = 8-9/
group): VEH D10, ASE D10, VEH D20, ASE D20, VEH D40, and ASE D40. All rats were
first repeatedly tested for avoidance performance 30 min after VEH (saline) or ASE (0.2 mg/
kg) injection for 5 consecutive days. After 7, 17 or 37 days of home cage rest, the rats were
given 2 retraining sessions and 1 challenge test in 3 consecutive days. On the challenge day,
the rats were injected with ASE (0.1 mg/kg) and tested for avoidance response in a 30-trial
CS-only session 30 min later. One additional ASE challenge test was conducted in all rats at
50 days after the last (5th) ASE treatment to evaluate possible group differences under the
same drug challenge condition. This test was conducted following 2 drug-free avoidance
retraining sessions (see Figure 1 for the experimental procedure and groups in details).
2.8. Statistical Analysis
Data (mean + SEM) from the 5 drug test sessions (e.g. avoidance response) were analyzed
using a split-plot repeated measures analysis of variance (ANOVA) with the between-
subjects factor being drug group and the within-subjects factor being drug-test session.
Differences between groups on the specific drug test days were analyzed using one-way
ANOVAs followed by post hoc Tukey’s HSD tests. Repeated measures ANOVA was also
used for analyzing locomotor activity test, with drug group and time-block as between- or
within-subject factor respectively. Data from the challenge tests were analyzed using a two-
way ANOVA, with treatment (RIS and VEH) and interval (10-, 20-, and 40-day) as two
between-subjects factors, followed by post hoc Tukey’s HSD tests. Significance was
predetermined at p < 0.05. All data was analyzed using SPSS Version 21.
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3. Results
3.1. Experiment 1: Effect of time interval between initial drug exposure and subsequent
drug challenge on the strength of risperidone sensitization
Avoidance response during the repeated RIS test period—No significant group
differences were found on the predrug day [F(5,45) = 0.549, p = 0.738]. Throughout the 5
days of RIS testing, avoidance response was suppressed by repeated RIS treatment.
Repeated measures ANOVA revealed a significant main effect of group [F(5,45) = 391.892,
p = 0.000], session [F(4,180) = 7.778, p = 0.000], but no significant interaction between the
two [F(20,180) = 0.855, p = 0.644] (Figure 2a).
Avoidance response on the retraining sessions—On the 1st retraining day (30 trials
of CS-only session), RIS-pretreated rats in the 20-day and 40-day groups, but not 10-day
group, had lower avoidances than their respective control groups. Independent samples t
tests showed that the RIS D20 differed significantly from VEH D20 [t(15) = 2.221, p =
0.042], and RIS D40 from VEH D40 [t(15) = 3.084, p = 0.008] (Figure 2b). The difference
between the 2 10-day groups was not significant [t(15) = 0.473, p = 0.643]. To further
illustrate this point, we calculated the group percentage of avoidance response by dividing
the group mean number of avoidance in the RIS-pretreated group by the mean number of
avoidance in its corresponding vehicle group (Figure 2c). Using this calculation, a lower
percentage of avoidance response indicates a stronger persistent impact of prior RIS
treatment. As Figure 2c shows, the group mean avoidance percentages were lower at 40 and
20 days than at 10 days, suggesting that the residual impact of prior RIS treatment increased
with the passage of time. No significant group difference was found on the 2nd retraining
day (ps > 0.083).
Avoidance response on the challenge test—On the 3 challenge tests at the 10-, 20-
and 40-day intervals, the 3 RIS groups all had lower avoidances than their VEH control
groups under the same RIS challenge [10-day groups, t(15) = 5.946, p = 0.002; 20-day
groups, t(15) = 5.319, p = 0.000; 40-day groups, t(15) = 3.723, p = 0.002; Figure 2d]. Two-
way ANOVA revealed a main effect of group [F(1, 45) = 72.392, p = 0.000] and interval
[F(2,45) = 4.360, p = 0.019], but no interaction between the two [F(2,45) = 1.869, p =
0.166]. Post hoc Tukey’s HSD tests comparing the interval differences found a significantly
lower avoidance at the 40-day interval than at the 10-day interval (p = 0.006). The RIS
sensitization effect appeared to be increased with the passage of time, as the relative group
avoidance percentage was lower in the RIS D40 group than other groups (Figure 2e).
3.2. Experiment 2: Effect of prior risperidone treatment on quinpirole-induced
hyperlocomotion
To test whether the D2 receptor system was involved in RIS sensitization, we tested
quinpirole-induced locomotor activity in rats that were pretreated with RIS (3 RIS groups)
or vehicle (3 VEH groups). This test was conducted at 50 days after the last (5th) RIS or
vehicle treatment. As shown in Figure 3, quinpirole at 1.0 mg/kg increased motor activity
during the 120-min test period, with an even higher motor activity found the RIS pretreated
rats than the VEH pretreated ones. Repeated measures ANOVA revealed a significant main
effect of time-block [F(11,506) = 114.795, p = 0.000], a significant block × group
interaction [F(11,506) = 2.473, p = 0.005], but no main effect of group [F(1,46) = 3.798, p =
0.057]. Independent samples t test at each block showed that the RIS group had significantly
higher motor activity than the VEH group on the last three 10-min blocks [100 min, t(46) =
−2.279, p = 0.027; 110 min, t(46) = −2.176, p = 0.035; 120 min, t(46) = −2.135, p = 0.038].
These data suggest that prior RIS treatment induced a long-lasting supersensitivity of D2/3
receptors, which may serve as a mechanism underlying RIS sensitization.
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3.3. Experiment 3: Effect of time interval between initial drug exposure and subsequent
drug challenge on the strength of asenapine sensitization
Avoidance response during the repeated ASE test period—During the initial 5
days drug testing, repeated ASE treatment suppressed avoidance response. Repeated-
measures ANOVA revealed a main effect of group [F(5,47) = 546.703, p = 0.000], session
[F(4,188) = 13.914, p = 0.000] and a significant interaction between the two [F(20,188) =
2.383, p = 0.001]. Inspection of Figure 4a reveals that the suppressive effect of ASE
increased across the 5 test sessions.
Avoidance response on the retraining sessions—On the 1st retraining day (30 trials
of CS-only session), only ASE-pretreated rats in the 40-day group had lower avoidance than
their vehicle controls [t(16) = 3.613, p = 0.002, Figure 4b]. The differences between the two
10-day [t(15) = 1.964, p = 0.068] and 20-day groups [t(16) = 1.042, p = 0.313] were not
significant. The mean group avoidance percentage also showed that the residual impact of
prior ASE treatment on avoidance response was greater at the 40-day interval than at other
intervals (Figure 4c). No significant group difference was found on the 2nd retraining day
(ps > 0.095).
Avoidance response on the challenge test—On the challenge days, all 3 ASE
groups had lower avoidances than their respective VEH groups. Two-way ANOVA showed
a main effect of group [Figure 4d, F(1, 47) = 67.486, p = 0.000] and a significant interaction
between group and interval [F(2,47) = 4.050, p = 0.024], suggesting that the RIS
sensitization effect varied across the 3 test intervals (Figure 4e). Independent samples t-test
confirmed that the 3 ASE groups all had significantly lower avoidances than their VEH
control groups [10-day groups, t(15) = 4.681, p = 0.000; 20-day groups, t(16) = 3.660, p =
0.002; 40-day groups, t(16) = 5.669, p = 0.000; Figure 4d].
Avoidance response on the final challenge test—To evaluate possible group
differences under the same condition, all 6 groups of rats were challenged with ASE at 0.1
mg/kg on the 50th day after the last ASE treatment. Before the challenge, there was no group
difference (> 70% avoidances, data not shown). On the challenge day, ASE-pretreated rats
had lower avoidance than the vehicle-pretreated ones (Figure 5). There was a main effect of
group [F(1, 47) = 18.094, p = 0.000], but no main effect of interval [F(2,47) = 0.589, p =
0.559], nor a group × interval interaction [F(2,47) = 0.538, p = 0.588]. Independent samples
t tests found a significant group difference between the ASE D10 and VEH D10 groups
[t(15) = 2.358, p = 0.032] and between the ASE D40 and VEH D40 groups [t(16) = 3.848, p
= 0.001], but not between the ASE D20 and VEH D20 [t(16) = 1.806, p = 0.090].
4. Discussion
Although antipsychotic sensitization effects have been demonstrated in the CAR model [8,
22, 24, 38] and other behavioral models [4, 5, 44-47], little research is devoted to
documenting the temporal feature of its development and related behavioral and receptor
mechanisms, especially those induced by newer atypical antipsychotic drugs (e.g. asenapine,
aripiprazole). The present study investigated the time-dependent feature of antipsychotic
sensitization in the CAR model and found: 1) both risperidone (1.0 mg/kg) and asenapine
(0.2 mg/kg) induced a long-lasting sensitization effect, detectable even 40 or 50 days after
the initial drug exposure; 2) the time-dependence of risperidone and asenapine sensitization
manifested mainly in the drug-free retraining session, less obvious under the drug challenge
test session due to the persistently lower avoidance responding in the 3 drug pre-treated
groups at the 3 test intervals; 3) risperidone-pretreated rats showed enhanced motor activity
under quinpirole challenge, suggesting that repeated risperidone treatment (and possibly
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asenapine, too) may induce a relatively permanent D2/3 receptor supersensitivity that
supports the long-lasting sensitization. Because suppression of avoidance response is
thought to be a behavioral measure of antipsychotic activity, the time-dependent feature of
enhanced efficacy due to past drug history may have clinical implications regarding the
therapeutic management of schizophrenia.
In many previous antipsychotic sensitization studies, the magnitude of sensitization is often
assessed at one single time point, several days or weeks after the initial drug treatment.
Thus, these studies were unable to provide much information regarding the changes in
sensitization with the passage of time. As mentioned in the Introduction, two basic
principles (TDS and forgetting) could govern the time-dependence of antipsychotic
sensitization, which give rise to two different predictions. According to the forgetting
principle, antipsychotic sensitization, as a basic form of non-associative learning and
memory, will decrease when the interval between the initial drug exposure (the induction/
learning phase) and the challenge test (the expression/memory phase) is prolonged. In
contrast, sensitization will increase with the passage of time on the basis of the TDS
principle due to the body’s adaptive and compensatory responses to a foreign agent. The
ultimate intensity of antipsychotic sensitization at any given time point likely reflects the
consequence of a joint action from these two forces. In our previous CAR study of
antipsychotic sensitization, we assessed haloperidol sensitization and olanzapine
sensitization at 3 time intervals (i.e., 4, 10, or 17 days), but did not find much change across
the 3 time points [8]. The present study extended the test time intervals up to 50 days after
the last drug treatment. We not only replicated risperidone[23, 38] and asenapine
sensitization [48], but also found their time-dependent feature. This feature was mainly
observed in the drug-free CS-only retraining/retesting sessions and was less obvious under
the drug challenge test sessions, consistent with our previous findings [8]. The risperidone
and asenapine sensitization effects, indexed by a suppression of avoidances, on the drug-free
retraining days increased with the passage of time. The D40 drug groups had significantly
fewer avoidance responses than the D40 vehicle groups on the 1st retraining day, whereas
the D10 groups did not differ from its vehicle controls (Fig. 2b and 4b). This increase in
antipsychotic sensitization was also observed in the group avoidance percentage measure
(Fig. 2c and 4c). Thus, it appears that the current test conditions were in favor of the
manifestation of TDS as opposed to forgetting. We do not know why we failed to
demonstrate the time-dependence of risperidone and asenapine sensitization in the drug
challenge tests. One possibility is that the initial tested dose and challenge dose of
risperidone and asenapine were still too high, causing a floor effect (i.e. a high dose causes a
large disruption of avoidance responding, leaving no room to show the residual impact of
prior risperidone or asenapine treatment), especially in the drug pretreated groups. As can be
seen in Figures 2a and 4a, risperidone and asenapine at the chosen doses suppressed
avoidance responding to the near bottom level even on the 1st test day. Similarly, on the
challenge tests (Figure 2d and 4d), the drug pretreated groups at the 3 test intervals all
displayed rather low levels of avoidance responding, causing difficulties in detecting their
potential differences. One important future study is to further manipulate experimental
conditions, including the utilization of different challenge doses, to delineate the exact
experimental conditions that would allow TDS to mediate time-dependent alterations of
antipsychotic sensitization.
The phenomenon of antipsychotic sensitization supports the notion that once an organism is
exposed to an antipsychotic drug, this drug experience stays with it for a long period of time
and may undergo a time-dependent change. Behaviorally, an antipsychotic drug may act as
an occasion-setter [49], which sets the condition in which rats behave on the basis of their
previous drug experience in the avoidance testing context. Neurobiologically, the
antipsychotic drug may imprint the brain to create a drug “memory trace” of avoidance
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responding under drug treatment by altering the functions of the neuroreceptors it targets.
Risperidone has a relatively high affinity for dopamine D2, serotonin 5-HT2A, 5-HT7, and
adrenergic α1 receptors [27] and asenapine has a high affinity for 5-HT2A, 5-HT2C, 5-HT6,
5-HT7, adrenergic α1 and α2, and histamine H1 and H2 receptors, and a relatively low action
on D2 and D1 receptors [26]. It is conceivable that 5 days of repeated risperidone and
asenapine treatment altered the functions of these receptors. Indeed, substantial evidence
suggests that chronic antipsychotic treatment does modify these neurochemical systems and
induces various forms of neuroplasticity [50-53]. For example, it has been shown that the
density and sensitivity of dopamine D2 receptors is upregulated after chronic antipsychotic
treatment, including risperidone and asenapine in both animals [54, 55] and humans [56]. In
the present study, using a behavioral assay of D2-mediated neurotransmission, we also
obtained evidence of a functional upregulation of D2 receptors caused by prior risperidone
exposure, as risperidone-pretreated rats had significantly higher motor activity than the
corresponding vehicle rats under quinpirole challenge. We hypothesized that D2 receptor
supersensitivity is one critical mechanism underlying antipsychotic sensitization (including,
olanzapine, risperidone and asenapine sensitization), and this conjecture is strengthened by
the following three observations. First, all antipsychotic drugs antagonize D2 receptors and
their chronic use causes a long-lasting change in this receptor system [57]. Second,
olanzapine sensitization in the CAR model also relies on D2 receptors. Li et al. (2010)
showed that pretreatment of quinpirole during the induction phase attenuated the expression
of olanzapine sensitization in the challenge test. Third, there exists a cross-sensitization
between risperidone and olanzapine [38] as well as asenapine and olanzapine [48], as rats
previously treated with risperidone or asenapine show enhanced responsiveness to
olanzapine in the suppression of avoidance responding. This hypothesis may warrant further
investigation. Because risperidone and asenapine also have relatively high 5-HT2A receptor
occupancies[58], and chronic risperidone and asenapine treatments decrease 5-HT2A
receptor binding in the medial prefrontal cortex [55, 59, 60], 5HT2A’s involvement in
risperidone and asenapine sensitization also needs to be examined. Other receptors such as
5-HT1A, D4, NMDA, and adrenergic α1 and α2 receptors could also play a role in
antipsychotic sensitization [26, 61-63].
Antelman et al. (2000) has argued that TDS is a useful principle for the explanation of
clinical improvement which grows with the passage of time [64]. One direct implication is
that “instead of managing disorders such as depression by multiple daily drug treatments, it
may be possible to accomplish the same ends by treating once every few weeks.” (page
354). In the case of clinical treatment of schizophrenia, psychotic symptoms do improve
exponentially with the passage of time and with the increase of treatment duration [3, 65],
but the relative contributions from each factor (i.e. time vs. treatment duration) on symptom
improvement has not been investigated. Currently, the most common practice in the clinic is
to treat schizophrenic patients with antipsychotic drugs daily to achieve approximately 60%
to 80% of dopamine D2 receptor occupancy [66]. If we do not need to maintain a daily
treatment schedule, it would avoid many side effects, including extrapyramidal symptoms
(EPS) and excess weight gain. Recent studies showing that dosing every 2-3 days is
sufficient to maintain antipsychotic efficacy in schizophrenic patients is in support of this
practice and TDS principle [67, 68]. This finding suggests that upon initial exposure,
physiological events initiated by a drug enhance the antipsychotic’s effects beyond its
presence at the receptor, thereby inducing efficacy without requiring constant receptor
binding. This idea is strongly supported by our current findings that risperidone and
asenapine sensitization persisted and even increased to some degree with the passage of
time. Previous studies in the literature generally suggest that continuous antipsychotic
treatment is more effective than interment antipsychotic regiment in preventing relapse in
people with schizophrenia [67, 68]. One problem with the previous intermittent approach is
that it allowed for lengthy “time off” and re-administration based on the re-appearance of
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symptoms. The current effective approach differs from the previous ones in which it
requires an intermittent but regular dosing regardless of symptom status [68]. Our findings
provide a preclinical support for this approach. Of course more preclinical and clinical
research is needed to address the potential benefits or harms of these two different drug
treatment regimens.
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1. Repeated risperidone and asenapine treatment enhanced acute effect of these
drugs in the conditioned avoidance model;
2. Risperidone and asenapine sensitization lasted up to 40 days;
3. Risperidone and asenapine sensitization increased with the passage of time;
4. Repeated risperidone treatment caused a functional upregulation of dopamine
D2/3 receptors.
Gao and Li Page 14
Behav Brain Res. Author manuscript; available in PMC 2014 November 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
A schematic depiction of the experimental procedures and groups in Experiment 1, 2 and 3.
CAR: conditioned avoidance response; VEH: vehicle; RIS: risperidone; ASE: asenapine.
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Figure 2.
The induction of risperidone (RIS) sensitization and its expression assessed at 3 time
intervals. Number of avoidance responses made by the rats on the final training (predrug)
day, five drug test days (a), and the first drug-free retraining day (b). Rats were injected with
RIS (1.0 mg/kg, sc, −60 min) or vehicle (VEH) and tested for avoidance responses for 5
daily sessions. D10, D20, or D40 groups (n = 8-9/group) received either 7, 17, or 37 days of
resting, and were then retrained in the conditioned avoidance response boxes for two
sessions. (c) The mean group avoidance percentage calculated by dividing the mean group
number of avoidance in the RIS group by that in its corresponding VEH group. (d, e) RIS
sensitization tested at 10-, 20- and 40-day intervals. All groups were injected with RIS (0.3
mg/kg, sc) and avoidance responses were measured 60 min later. All data are expressed as
mean + SEM. ***p < 0.001, **p < 0.01, *p < 0.05 for comparison to the respective VEH
group.
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Figure 3.
Quinpirole-induced locomotor activity in rats that were pretreated with risperidone (RIS, 1.0
mg/kg) for 5 days. The test was conducted 50 days after the last RIS (1.0 mg/kg) treatment.
All rats were injected with quinpirole (1.0 mg/kg, sc) and then measured for motor activity
for 120 min. All data are expressed as mean + SEM in 12 10-min blocks. *p < 0.05 for
comparison to the respective VEH group.
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Figure 4.
The induction of Asenapine (ASE) sensitization and its expression assessed at 3 time
intervals. Number of avoidance responses made by the rats on the final training (predrug)
day, five drug test days (a), and the first drug-free retraining day (b). Rats were injected ASE
(0.2 mg/kg, sc, −30 min) or vehicle (VEH) and tested for avoidance responses for 5 daily
sessions. D10, D20, or D40 groups (n = 8-9/group) received either 7, 17, or 37 days of
resting, and were then retrained in the conditioned avoidance response boxes for two
sessions. (c) The mean group avoidance percentage calculated by dividing the mean group
number of avoidance in the ASE group by that in its corresponding VEH group. (d, e) ASE
sensitization tested at 10-, 20- and 40-day intervals. All groups were injected with ASE (0.1
mg/kg, sc) and avoidance responses were measured 30 min later. All data are expressed as
mean + SEM. ***p < 0.001, **p < 0.01 for comparison to the respective VEH group.
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Figure 5.
The expression of Asenapine (ASE) sensitization assessed after a 50-day interval. Number
of avoidance responses (a) and the mean group avoidance percentage (b) made by the rats on
the challenge day. After retraining in the conditioned avoidance response boxes for two
sessions, all groups were injected with ASE (0.1 mg/kg, sc) and avoidance responses were
measured 30 min later on 50th day after the last drug test (ASE 0.2 mg/kg). All data are
expressed as mean + SEM. **p < 0.01, *p < 0.05 for comparison to the respective VEH
group.
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